Date: 2015-07-15
Type of information: Nomination
Compound:
Company: Erytech Pharma (France)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 15, 2015, Erytech Inc., the US affiliate of Erytech Pharma,the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announced the appointment of Iman El-Hariry as Chief Medical Officer, responsible for global medical, clinical and regulatory affairs.Iman El-Hariry, M.D., Ph.D., is an oncologist with more than 15 years of global product development experience in the global biopharmaceutical ind ustry, including as VP Clinical Research with Syntha Pharmaceuticals (Boston), Global Head Oncology at Astellas APGD (Chicago) and Group Director Clinical Oncology at GSK (London). She has successfully led the development and regulatory approvals of different products both in Europe and in the United States. As Chief Medical Officer at Erytech Inc, based in Boston, Iman will be responsible for global medical, clinical and regulatory affairs. Her key priorities will be the registration of ERYASP/GRASPA® in Europe in Acute Lymphoblastic Leukemia, the supervision of the ongoing clinical studies in AML and Pancreas cancer in Europe, and the development of ERYASP in the United States. She has already been advising the company on a consulting basis over the past months. Dr. El-Hariry holds an M.D. (Hons) from Alexandria Medical School, Alexandria, Egypt and a Ph.D. from the Imperial College of Science and Medicine, London, UK.
Financial terms:
Latest news:
